|
Immudex is a Danish Reagents and Diagnostics company established in 2009. The company is operating from offices located in Copenhagen, Denmark, and in Fairfax, Virginia. Immudex specializes in the production of MHC Dextramers. MHC Dextramers are chemical reagents that are designed to detect antigen-specific T cells.〔Davis MM, Altman JD, Newell EW. “Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis”. Nat Rev Immunol. 2011 Jul 15;11(8):551-8. doi: 10.1038/nri3020.〕 All Immudex products, whether on the marked or in development, are based on its proprietary MHC Dextramer technology. The use of MHC Dextramers offers a new method to accurately detect and quantify antigen-specific CD8+ T cells. While some of the technology is currently only sold for Research use only (RUO), clinical applications are being actively pursued. Currently, Immudex has several development projects for clinically applicable MHC Dextramers. Even so, the first MHC Dextramers clinical reagent has been developed and approved for clinical in vitro diagnostics in Europe. Namely the CE-marked kit for enumeration of cytomegalovirus-specific T cells. Immudex primarily focuses on the identification of producing large quantities of CD8+ T cells by the means of MHC class I molecules. Even so, the research and development into the application of MHC class II Dextramers might expand the technology. == History == Originally, Immudex operated as an individual division within the much larger Danish pharmaceutical company Dako. Immudex was later spun out as a separate business, when the focus of Dako largely shifted to cancer diagnostics.〔〔Børsen, Oct. 9th, 2009, Tom Frovst. "Milliardpotentiale i Dako-satsning". Copenhagen, DK. pg. 8.〕 Immudex currently have clients world wide with major markets in the United States and Europe. Patents for the MHC Dextramer technology were filed at Dako in 2001, and the Immudex division was launched in 2005. In 2011, Immudex received the prestigious “Entrepreneur of the Year 2011” award in the Life Sciences category granted by Ernst & Young.〔Ernst & Young, Nov. 24th, 2011. "Immudex vinder kategorien Life Sciences Entrepreneur Of The Year 2011". Copenhagen, DK〕 Immudex received this award because of the commitment of the company, articulated in the company's "make it work and make it better" strategy to generate results for both practitioners and patients. The award is given to companies not only focused on financial growth, but also for softer values such as the entrepreneur's social responsibility and the ability to aspire an motivate the organization. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Immudex」の詳細全文を読む スポンサード リンク
|